INTRODUCTION AND OBJECTIVES: Post Vasectomy Pain
Syndrome (PVPS) is an uncommon urological problem that remains a challenge to manage. We aim to evaluate the outcomes of patients who underwent microdenervation of the spermatic cord (MDSC) for PVPS at our institution.
METHODS: A retrospective study of 161 patients who underwent MDSC by a single surgeon from March 2002 to October 2016. Pain was documented using the visual analogue scale (VAS). Spermatic cord block (SCB) was performed on all patients and success was defined as VAS ¼1 for >4 hours. Patients who responded to a SBC were candidates for MDSC. All patients failed medical therapy prior to MDSC. All prior procedures for PVPS were performed elsewhere. Surgical success was defined as postoperative VAS of ¼1.
RESULTS: 29 patients underwent MDSC for PVPS. Median follow up was 37 months (1st quartile 20 months, 3rd quartile 100 months). Median duration of pain prior to surgery was 57 months (1st quartile 36months, 3rd quartile 112 months). Pain was bilateral in 14 (48%), left in 11 (38%) and right in 4 (14%) patients. 9 patients (31%) had worsening pain on ejaculation. Data on SCB was available on 23 patients with success rate of 96%. Median preoperative pain on VAS score was 7 (range 2-10). Median pain following SCB on VAS score was 0 (range 0-5). Median postoperative pain on VAS score was 0 (range 0-9). Success was obtained in 71% of patients and patients with involvement of multiple structures in the scrotum (ie: testis, epididymis, spermatic cord) are more likely to have a successful surgery, p¼0.016. 5 patients failed a prior epididymectomy and 3 patients failed a vaso-vasostomy for PVPS and this had no correlation with the success of MDSC, p¼0.89 CONCLUSIONS: MDSC is successful and durable in 71% of our patients and is a valuable approach for PVPS especially when pain involves multiple structures in the scrotum (ie: testis, epididymis, spermatic cord). MDSC is equally as effective on patients who had previously failed a prior procedure for PVPS. All but three patients with PVPS had improvement in VAS following MDSC. No patient had a worsening VAS following MDSC. This is the largest study to date evaluating MDSC for the treatment of PVPS. Chronic pelvic pain and orchalgia are challenging conditions to treat in urologic practice. Recent research and treatment have begun to focus on musculoskeletal dysfunction as a major contributor to pelvic pain and orchalgia. The objective of this study is to assess the clinically reported outcomes of patients in our center that presented with orchalgia who underwent physical therapy.
METHODS: A retrospective chart review was conducted on men who initially presented to our practice with orchalgia from January 2009 to June 2016 and referred for pelvic floor physical therapy. Each patient had a urologic assessment prior to physical therapy referral. Patients were evaluated and treated by our physical therapy team according to any presenting musculoskeletal impairments/complaints. Treatments included pelvic alignment exercises, therapeutic stretching/strengthening, manual therapy, dry needling and biofeedback. Following treatment, a subjective global response measure was assessed based on patients 0 self-reports of improvement. Additionally, if available, NIH Chronic Prostatitis Symptom Index (NIH-CPSI) data was collected. Statistical analysis was performed in SAS 9.4 (SAS Institute, Cary, NC) where all P-values less than 0.05 were considered statistically significant.
RESULTS: A total of 392 patient charts met inclusion criteria for this retrospective study. Average age was 42.8 years with mean longevity of symptoms of 32.8 months. 49.1% had co-existing urinary complaints. Pre-treatment average day pain was 4.5 (analog scale 1-10); worst day pain was 7.6. 83.2% of patients indicated their testicular pain was better, 16.1% reported no change and 0.7% reported worsening of their pain at average follow up of 6.4 months. 150 patients (38%) completed a NIH-CPSI questionnaire both pre and post treatment. Of these patients, those who reported improvement in their pain (n¼138) had decrease in pain scores from average of 16.7 to 11.3, decrease in urinary score from 2.6 to 2.0, and improvement in quality of life score from 8.1 to 4.2; each was statistically significant (p<0.01). Patients who did not improve or had worsening of symptoms with physical therapy (n¼12) did not have statistically significant improvement in pain, urinary or quality of life scores (p¼0.36, p¼0.78, p¼0.17; respectively).
CONCLUSIONS: Physical therapy serves as a valid and effective treatment option for patients with orchalgia, following a comprehensive urologic examination. The significant subjective and objective improvement reported by this group of patients with no adverse side effects points towards early referral to a pelvic physical therapy practice. METHODS: Total of 68 patients were randomized into two groups. Group A (n¼32) received alfuzosin and levofloxacin (standard treatment) whereas group B (n¼ 36 ) received tadalafil 5mg (PDE 5 inhibitor) in addition to alfuzosin and levofloxacin for 6weeks.The groups were analyzed pre and post treatment with National Health Institute Chronic Prostatitis Symptom Index (NIH-CPSI), International Index of Erectile Function (IIEF-5), International Prostate Symptom Score(IPSS), scores and uroflowmetry.
RESULTS: Changes observed in the NIH-CPSI of group B at six weeks were greater than those at baseline (group A, -8.4 vs. group B, -18.0; p<0.05). The mean change in total IPSS from baseline was higher in group B than that in group A (group A, -3.4 vs. group B, -8.8; p <0.05). Change in IPSS-QOL index from baseline was significant in Group B (group A, -0.63 vs. group B,-2.03 ; p<0.05). Group B showed a significantly greater increase in the IIEF-EF score than group A (group A -0.7 vs. group B +6.4; p<0.05). Qmax pre and post therapy showed significant improvement in group B when adjusted for age (group A, -2.9 vs group B, +2.56; p<0.05).
CONCLUSIONS: PDE-5 inhibitor results in significant improvement in CP/CPPS symptoms and quality of life and is well tolerated. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e119
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